CureDuchenne is pleased to share news that Avidity Biosciences has announced exciting details of its Duchenne program today, the full press release is below. CureDuchenne Ventures made an investment in […]
— Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo — — SRP-9001-treated participants showed […]
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational […]
– Pivotal program for RGX-314, potential best-in-class, one-time gene therapy for the treatment of wet AMD, is active and expected to support BLA filing in 2024— Recently completed an End […]
Newport Beach, CA, December 21, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today a new initiative to deliver […]
Dear Committee Members, On behalf of individuals living with Duchenne muscular dystrophy, their families, and caregivers served by CureDuchenne, I am writing to urge the Committee to include individuals with Duchenne in its recommendations for sub-populations to receive approved or authorized COVID-19 […]
Loss of bone density and strength is a common problem in Duchenne muscular dystrophy, and can lead to frequent fractures, chronic spine pain and deformity, and premature loss of ambulation. […]
CureDuchenne Ventures is happy to announce its latest research funding is an investment in PepGen, a therapeutics company targeting Duchenne muscular dystrophy and other neuromuscular diseases with next-generation antisense oligonucleotides. […]
— Results from the multiple–ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation — — At a total dose exposure approximately 10x lower than eteplirsen, SRP-5051 at 20 mgs/kg showed enhanced tissue exposure, greater […]
